Applied Therapeutics, Inc. (APLT)

Applied Therapeutics' stock price has experienced a significant decline over the past six months and year. As of January 9, 2026, the share price was $0.10. A major event impacting the stock was the FDA's Complete Response Letter (CRL) for govorestat (AT-007) for classic galactosemia. News emerged of a potential acquisition of Applied Therapeutics by Cycle Pharmaceuticals, accompanied by shareholder alerts and investigations.

Analysis of Applied Therapeutics, Inc. seasonal charts suggests a historical seasonal pattern with a "Buy Date of November 10 and a Sell Date of February 3", resulting in a geometric average return of 15.43% above the S&P 500 Total Return Index. This seasonal timeframe has shown positive results compared to the benchmark in 4 out of 5 periods. The seasonal timeframe correlates poorly with the broader Healthcare sector's seasonal strength, which typically runs from April 25 to December 4.

Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing novel small-molecule therapies for genetically defined diseases with high unmet medical needs, operating within the Healthcare sector, specifically in the Biotechnology and Pharmaceutical Products industry. AT-007 (govorestat) has completed Phase 3 trials for galactosemia in healthy volunteers and adults, is in pediatric clinical study for galactosemia in children, and is also being investigated for treating SORD deficiency and phosphomannomutase enzyme-CDG; the company has an exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. AT-001 is in Phase 3 clinical trials for diabetic cardiomyopathy and is also being studied for diabetic peripheral neuropathy. AT-003 is currently in preclinical studies for diabetic retinopathy. AT-104 is a PI3K inhibitor in preclinical stage for treating orphan hematological oncology T Cell Acute Lymphoblastic Leukemia.

Applied Therapeutics, Inc. is headquartered in New York, New York, United States. The company supports its preclinical and clinical operations through collaborative partnerships with academic research institutions and contract research organizations across North America and Europe.

Applied Therapeutics' brand reputation has likely been significantly affected by the FDA's Complete Response Letter (CRL) for govorestat. The ongoing shareholder alerts and investigations related to the potential acquisition by Cycle Pharmaceuticals could also contribute to a perception of uncertainty or instability, further influencing brand reputation.

Applied Therapeutics is primarily owned by institutional shareholders (65.67%), followed by retail investors (25.68%), and company insiders (8.65%). Major institutional owners include T. Rowe Price Investment Management Inc., Vestal Point Capital LP, Propel Bio Management LLC, Knoll Capital Management LLC, Vanguard Group Inc, Simplify Asset Management Inc, Blackrock Inc, PNC Financial Services Group Inc, and Pathstone Holdings LLC. The largest individual shareholder is Shoshana Shendelman, who owns 6.05 million shares, representing 4.19% of the company.